|
2020-04-25 Science & Technology
|
|
UW Medicine to conduct clinical trial for hydroxychloroquine with COVID patients
|
Geek Wire via Instapundit
The University of Washington School of Medicine is looking for people who have tested positive for COVID-19 to participate in a clinical trial aimed at finding out whether a controversial drug called hydroxychloroquine can keep them from having to be hospitalized.
Word of UW Medicine’s clinical trial comes after reports about a study at Veterans Health Administration medical centers in which COVID-19 patients who took hydroxychloroquine, which is typically used to treat malaria and autoimmune disease, died at higher rates than those who didn’t take the drug.
Today, the Food and Drug Administration warned that hydroxychloroquine carries "known risks" of potentially deadly heart complications — and said the drug should be used in supervised settings such as clinical trials, where the risks can be better studied and mitigated.
The Department of Veterans Affairs’ study involved patients who were being hospitalized for COVID-19. UW Medicine’s study, in contrast, will focus on patients who have tested positive for COVID-19 but aren’t sick enough to be in a hospital. The new study will be randomized, unlike the VA study, which should lead to more reliable results.
"We are recruiting patients with recently diagnosed COVID infection and hope to show whether early treatment can keep them from having to be admitted to the hospital," co-principal investigator Christine Johnston, an associate professor of medicine at UW, said today in a news release. "We are studying whether the early treatment of COVID-19 prevents viral pneumonia and also seeing if the medications decrease viral shedding, which could have a potential benefit of reduced transmission of COVID-19."
The trial will gauge the effectiveness of hydroxychloroquine as well as a combination of the drug with azithromycin, an antibiotic.
Two cohorts of outpatients will be enrolled in the trial, in high-risk and low-risk categories. Patients who are older than 60 or have underlying conditions such as diabetes, hypertension, obesity or lung problems are considered high-risk. Patients who are aged 18 through 59 without such conditions are considered low-risk.
Coronavirus Live Updates: The latest COVID-19 developments in Seattle and the world of tech
More than 600 patients in all will be enrolled at sites across the country, including UW as well as medical facilities in Boston, New Orleans, Chicago and Syracuse, N.Y.
...The $5.8 million trial is funded by the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome and Mastercard, with support from an array of public and philanthropic donors.
No doubt all part of the Gate's nefarious plot to take over the World
|
Posted by g(r)omgoru 2020-04-25 04:37||
||
Front Page|| [11130 views ]
Top
|
|
Posted by gorb 2020-04-25 10:36||
2020-04-25 10:36||
Front Page
Top
|
|
Posted by Clem 2020-04-25 11:10||
2020-04-25 11:10||
Front Page
Top
|
|
Posted by Bobby 2020-04-25 13:16||
2020-04-25 13:16||
Front Page
Top
|
|
Posted by g(r)omgoru 2020-04-25 13:18||
2020-04-25 13:18||
Front Page
Top
|
|
Posted by Whiskey Mike 2020-04-25 13:19||
2020-04-25 13:19||
Front Page
Top
|
|
11:11 HeavyG
11:10 Angstrom
11:07 HeavyG
11:07 Angstrom
11:06 DarthVader
11:05 HeavyG
10:58 alanc
09:43 Mullah Richard
09:27 Warthog
09:11 Mercutio
09:07 AlmostAnonymous5839
08:52 Matt
08:24 Matt
08:20 SteveS
07:43 Procopius2k
07:42 BrerRabbit
07:42 Procopius2k
07:39 Procopius2k
07:36 Procopius2k
07:35 Procopius2k
07:34 trailing wife
07:31 Procopius2k
07:30 NN2N1
07:22 NN2N1
|
